Imugene (ASX:IMU) received a notice of allowance from the US Patent and Trademark Office for patent application number 16/637,909, protecting its oncolytic virotherapy CF33-CD19 and its combination with CD19 targeting CAR T cell therapies, according to a Wednesday filing with the Australian bourse.
The patent offers protection for the method of composition and method of use through to Aug. 10, 2038, the filing said.
Shares fell past 7% in midday trade Wednesday and hit their lowest since January 2018.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。